Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019007836) NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/007836 International Application No.: PCT/EP2018/067573
Publication Date: 10.01.2019 International Filing Date: 29.06.2018
IPC:
C07D 471/14 (2006.01) ,A61K 31/166 (2006.01) ,A61K 31/4375 (2006.01) ,A61K 31/439 (2006.01) ,C07D 471/18 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
12
in which the condensed system contains three hetero rings
14
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
165
having aromatic rings, e.g. colchicine, atenolol, progabide
166
having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
4375
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
439
the ring forming part of a bridged ring system, e.g. quinuclidine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
12
in which the condensed system contains three hetero rings
18
Bridged systems
Applicants:
UNIVERSITÄT REGENSBURG [DE/DE]; Universitätsstraße 31 93053 Regensburg, DE
Inventors:
MAHBOOBI, Siavosh; DE
PONGRATZ, Herwig; DE
GRÜNSTEIN, Elisabeth; DE
Agent:
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB; Markus ENGELHARD Pettenkoferstraße 22 80336 München, DE
Priority Data:
17180002.206.07.2017EP
Title (EN) NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES
(FR) NOUVEAUX INHIBITEURS DE HDAC6 ET LEURS UTILISATIONS
Abstract:
(EN) The present invention relates to small molecule compounds and their use as HDAC inhibitors and their use in the treatment of various diseases, such as cancer. The present invention further relates to methods for improvement of solubility by introducing basic substituents which offer the opportunity to create pharmaceutically acceptable salts. Moreover, it comprises methods of synthesizing the compounds and methods of treatment.
(FR) La présente invention concerne des composés à petites molécules et leur utilisation en tant qu'inhibiteurs de HDAC ainsi que leur utilisation dans le traitement de diverses maladies, telles que le cancer. La présente invention concerne également des procédés d'amélioration de la solubilité par introduction de substituants basiques qui offrent la possibilité de créer des sels pharmaceutiquement acceptables. L'invention concerne en outre des procédés de synthèse des composés, et des méthodes de traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)